目的 探討牛黃降壓片聯(lián)合硝苯地平緩釋片治療原發(fā)性高血壓的臨床療效。方法 選取2019年3月—2019年6月在成都市第七人民醫(yī)院治療的原發(fā)性高血壓患者86例，根據(jù)用藥差別分為對(duì)照組（43例）和治療組（43例）。對(duì)照組口服硝苯地平緩釋片，20 mg/次，2次/d；治療組在對(duì)照組基礎(chǔ)上口服牛黃降壓片，2 g/次，1次/d。兩組患者均經(jīng)4周治療。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者血壓變化，SPIEGEL、SAS、SDS和GQOL-74評(píng)分，及血清同型半胱氨酸（Hcy）、血管性血友病因子（vWF）、可溶性細(xì)胞間黏附分子-1（sICAM-1）、可溶性凝集素樣氧化低密度脂蛋白受體1（sLOX-1）、血管緊張素Ⅱ（AngⅡ）水平。結(jié)果 治療后，對(duì)照組和治療組臨床有效率分別為81.40%和97.67%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。經(jīng)治療，兩組收縮壓（SBP）、舒張壓（DBP）均顯著下降（P<0.05），且治療組患者血壓水平明顯好于對(duì)照組患者（P<0.05）。經(jīng)治療，兩組患者SPIEGEL評(píng)分、SAS評(píng)分和SDS評(píng)分明顯降低（P<0.05），但是GQOL-74評(píng)分明顯升高（P<0.05），且治療組患者這些評(píng)分明顯好于對(duì)照組（P<0.05）。經(jīng)治療，兩組血清Hcy、vWF、sICAM-1、sLOX-1、AngⅡ水平均明顯降低（P<0.05），且治療組明顯低于對(duì)照組（P<0.05）。結(jié)論 牛黃降壓片聯(lián)合硝苯地平緩釋片治療原發(fā)性高血壓可有效控制血壓水平，改善患者負(fù)面情緒、睡眠及生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Niuhuang Jiangya Tablets combined with nifedipine in treatment of essential hypertension. Methods Patients (86 cases) with essential hypertension in Chengdu Seventh People's Hospital Chinese from March 2019 to June 2019 were divided into control (43 cases) and treatment (43 cases) groups based on different treatments. Patients in the control group were po administered with Nifedipine Sustained-release Tablets, 20 mg/time, twice daily. Patients in the treatment group were po administered with Niuhuang Jiangya Tablets on the basis of the control group, 2 g/time, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the change of blood pressure, the scores of SPIEGEL, SAS, SDS and GQOL-74, SAQ and GQOLI-74 scores, the serum levels of Hcy, vWF, sICAM-1, sLOX-1 and AngⅡ in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 81.40% and 97.67% respectively, and there were differences between two groups (P<0.05). After treatment, the SBP and DBP in two groups was significantly decreased (P<0.05), and the blood pressure in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the scores of SPIEGEL, SAS and SDS in two groups were significantly decreased (P<0.05), but the GQOL-74 scores were significantly increased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum levels of Hcy, vWF, sICAM-1, sLOX-1, and AngⅡ in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Niuhuang Jiangya Tablets combined with nifedipine in treatment of essential hypertension can effectively control blood pressure level, improve patients' negative emotions, sleep and quality of life, which has a certain clinical application value.

R972